Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

News Releases

Date Title and Summary
Toggle Summary electroCore and UpScript Launch Program to Offer Direct-to-Patient Telemedicine Option for gammaCore™ in the United States
BASKING RIDGE, N.J., July 17, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, announced today a program with UpScript, a digital healthcare platform, offering a direct-to-patient telemedicine option for gammaCore™ non-invasive vagus nerve
Toggle Summary electroCore Announces Appointment of New Chief Medical Officer
Peter Staats MD, MBA, ABIPP, FIPP Joins electroCore to Lead Global Development of Company’s Non-invasive Vagus Nerve Stimulation (nVNS) Therapy   Basking Ridge, NJ, June 21, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological
Toggle Summary electroCore Announces Data Presentation at the 69th American Academy of Neurology Annual Meeting
Data from ACT2 Clinical Trial of gammaCore ®  in Cluster Headache Presented for First Time Yesterday During Emerging Science Session   Basking Ridge, NJ, April 26, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement,
Toggle Summary electroCore Announces Results from gammaCore® (non-invasive vagus nerve stimulator) Study in Migraine at the 18th Congress of the International Headache Society
PRESTO demonstrates clinical benefit of gammaCore in the acute treatment of migraine compared to sham  Basking Ridge, NJ, September 11, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced the first results
Toggle Summary ElectroCore appoints Desitin to launch gammaCore for the treatment of primary headache across Germany
Basking Ridge, New Jersey: ElectroCore’s non-invasive vagus nerve stimulation device, gammaCore, will be launched across Germany by Desitin for the treatment of migraine and cluster headache. The agreement with Desitin who are specialists in the CNS area took effect on January 1st, 2016.  Desitin,
Toggle Summary electroCore CEO to Join Company’s Board of Directors
Francis R. Amato to Take on Additional Role to Help Further Position the Company for Growth       Basking Ridge, NJ, June 21, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that Chief Executive
Toggle Summary electroCore Completes $70 Million Series B Funding Round
Investment to fund commercialization of gammaCore ®  and further clinical development of nVNS   Basking Ridge, NJ, November 29, 2017  – electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced
Toggle Summary electroCore Expands Manufacturing Capabilities for gammaCore™
BASKING RIDGE, N.J. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc.  (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced expansion into a new design and development facility to support increasing patient demand of its gammaCore™ non-invasive vagus
Toggle Summary electroCore Receives 510(k) Clearance for gammaCore-S® (non-invasive vagus nerve stimulator) for the Acute Treatment of Pain Associated with Episodic Cluster Headache in Adult Patients
Regulatory clearance marks most recent achievement in new device being available to the approximately 400,000 Americans living with episodic cluster headaches     Basking Ridge, NJ, June 15, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through
Toggle Summary electroCore Receives FDA Clearance for gammaCore™ (nVNS) for Adjunctive Use for the Preventive Treatment of Cluster Headache in Adults
BASKING RIDGE, N.J. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration ( FDA ) for an expanded label for gammaCore™ [non-invasive vagus